SEC Form 4 · accession 0001209191-15-032711
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lee Kalowski
Officer — Chief Financial Officer
Period of report
Apr 2, 2015
Accepted (ET)
Apr 6, 2015 · 5:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Apr 2, 2015 | S | 2,258 | $11.45 | D | 52,346 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares were sold to satisfy certain tax obligations of the Reporting Person triggered by the vesting of certain restricted stock units. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.30 per share to $11.66 per share. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3Represents 4,567 shares of common stock held by the Reporting Person and 47,779 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock upon vesting.